Predicting treatment risk using geriatric assessment and genetic profiling for AML may impact early rates of mortality among patients aged 60 years or older. Geriatric assessment showed a high rate of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback